We see firsthand how GLP-1 medications like Ozempic and Mounjaro can impact people differently
Increasingly, it is expected to work with the body rather than against it
NIDDK estimates about 36% of people in the United States have lactose malabsorption, and typical label comparisons show whey protein isolate is far lower in lactose than whey protein concentrate (often up to about 1 gram lactose vs up to about 3.5 grams lactose per similar 100-calorie serving)
Ezen a vlemnyen van az Ausztrl Orvosi Szvetsg egyik elnke, Michael Page is: Az elnyk nmelyike kicsit spekulatv, egy kicsit tbb idre s megfelelen megtervezett klinikai vizsglatokra van szksgnk ahhoz, hogy biztosak lehessnk bennk. A GLP-1 analgok egyik kzs ismrve, hogy mg a tlslyra sem jelentenek vgrvnyes megoldst
For example, in one letter the following was flagged as offending language, despite not naming the branded products: Doctors frequently recommend Compounded Tirzepatide or Compounded Semaglutide, both of which are GLP-1 agonists with the same active ingredient as the brand name medications. In another letter, the only offending language was: Clinically proven weight loss treatments. The FDA said this language implies that [the sellers] products are the same as an FDA-approved product when they are not. Whats Next
It gives you a structured way to track the variables the science identifies as relevant - protein, training, recovery, composition trends - so you and your prescriber have real data to work with rather than a vague sense of how things are going
